

PUBLICATIONS 2017

SERVICE DE BIOSTATISTIQUE ET D'EPIDEMIOLOGIE

BIOSTATISTICS AND EPIDEMIOLOGY DEPARTMENT

1. Andreiuolo F, Le Teuff G, Bayar MA, Kilday JP, Pietsch T, von Bueren AO, Witt H, Korshunov A, Modena P, Pfister SM, Pagès M, Castel D, Giangaspero F, Chimelli L, Varlet P, Rutkowski S, Frappaz D, Massimino M, Grundy R, Grill J. Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. *PLoS ONE*. 2017;12:e0178351. doi: 10.1371/journal.pone.0178351. PubMed PMID: 28617804.
2. Angevin E, Cassier PA, Italiano A, Goncalves A, Gazzah A, Terret C, Toulmonde M, Gravis G, Varga A, Parlavecchio C, Paci A, Poinsignon V, Soria JC, Drubay D, Hollebecque A. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. *European journal of cancer*. 2017;83:194-202. Epub 2017/07/28. doi: 10.1016/j.ejca.2017.06.036. PubMed PMID: 28750271.
3. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Taberero J, Cervantes A, Ciardiello F. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Ann Oncol*. 2017;28:1713-29. doi: 10.1093/annonc/mdx175. PubMed PMID: 28407110.
4. Aspeslagh S, Matias M, Palomar V, Dercle L, Lanoy E, Soria JC, Postel-Vinay S. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? *Eur J Cancer*. 2017;87:65-74. doi: 10.1016/j.ejca.2017.09.027. PubMed PMID: 29126088.
5. Atlan P, Bayar MA, Lanoy E, Besse B, Planchard D, Ramon J, Raynard B, Antoun S. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. *Support Care Cancer*. 2017;25:3365-73. doi: 10.1007/s00520-017-3755-z. PubMed PMID: 28593463.
6. Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM. A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. *Cancer Res*. 2017;77:557-65. doi: 10.1158/0008-5472.CAN-16-1733. PubMed PMID: 27836854.
7. Bautista F, Moreno L, Marshall L, Pearson ADJ, Geoerger B, Occean BV. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. *Eur J Cancer*. 2017 Nov;86:275-284. doi: 10.1016/j.ejca.2017.09.015. Pubmed PMID: 29055843
8. Bayar MA, Antoun S, Lanoy E. Statistical approaches for evaluating body

composition markers in clinical cancer research. *Expert Rev Anticancer Ther.* 2017;17:311-8. doi: 10.1080/14737140.2017.1298446. PubMed PMID: 28277100.

9. Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavaille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Occean BV, Servois V, Le Tourneau C. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. *Ann Oncol.* 2017;28:590-6. doi: 10.1093/annonc/mdw666. PubMed PMID: 27993804.
10. Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN, Ferru A, Buffet C, Chabre O, Huillard O, Leboulleux S, Schlumberger M. Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice. *Thyroid.* 2017. doi: 10.1089/thy.2017.0205. PubMed PMID: 29048237.
11. Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. *Ann Oncol.* 2017;28:1078-83. doi: 10.1093/annonc/mdx070. PubMed PMID: 28327934.
12. Blanchard P, Foulon S, Louvel G, Habibian M, Fizazi K. [A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial]. *Cancer Radiother.* 2017;21:491-4. doi: 10.1016/j.canrad.2017.06.007. PubMed PMID: 28869198.
13. Boros A, Lacroix L, Lacas B, Adam J, Pignon JP, Caramella C, Planchard D, de Montpreville V, Deutsch E, Levy A, Besse B, Le Pechoux C. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. *Oncotarget.* 2017;8:25189-99. doi: 10.18632/oncotarget.15966. PubMed PMID: 28445990.
14. Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice? *Clinical trials.* 2017;14(1):78-87. Epub 2016/10/13. doi: 10.1177/1740774516673362. PubMed PMID: 27729499.
15. Bredart A, Bodson S, Le Tourneau C, Flahault C, Bonnetain F, Beaudeau A, Coquan E, Dolbeault S, Occean BV. Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study. *European journal of cancer care.* 2017;26(6). Epub 2016/10/14. doi: 10.1111/ecc.12596. PubMed PMID: 27734561.
16. Caron O, Frebourg T, Benusiglio PR, Foulon S, Brugières L. Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial. *JAMA Oncol.* 2017. doi: 10.1001/jamaoncol.2017.1358. PubMed PMID: 28772306.
17. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Ann Oncol.* 2017;28:1368-79. doi: 10.1093/annonc/mdx108. PubMed PMID: 28368458.
18. Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C,

- Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. *Eur J Cancer*. 2017;80:55-62. doi: 10.1016/j.ejca.2017.03.011. PubMed PMID: 28549248.
19. Conversano A, Mazouni C, Thomin A, Gaudin A, Fournier M, Rimareix F, Bonastre J. Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma. *Clin Breast Cancer*. 2017;17:293-7. doi: 10.1016/j.clbc.2016.12.013. PubMed PMID: 28161131.
 20. Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. *Ann Oncol*. 2017. doi: 10.1093/annonc/mdx691. PubMed PMID: 29077781.
 21. Daroles J, Borget I, Suci V, Mazouni C, Delalogue S, Balleyguier C. Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? *Eur J Cancer*. 2017;85:23-30. doi: 10.1016/j.ejca.2017.08.002. PubMed PMID: 28881248.
 22. Desportes E, Wagner M, Kamal M, Salomon AV, Denizaut G, Pierron G, Rouleau E, Jouffroy T, Le Tourneau C, Occean BV, Servois V. Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. *Oncotarget*. 2017;8(1):1760-73. Epub 2016/09/23. doi: 10.18632/oncotarget.12051. PubMed PMID: 27655703; PMCID: 5352095.
 23. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Semin Cancer Biol*. 2017. doi: 10.1016/j.semcancer.2017.10.003. PubMed PMID: 29024776.
 24. Ducreux M, Österlund P, Pignon JP. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion? *Semin Oncol*. 2017;44:129-31. doi: 10.1053/j.seminoncol.2017.07.002. PubMed PMID: 28923210.
 25. Dutot C, Mercier G, Borget I, de Sauvebeuf C, Martelli N. HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT FOR THE ADOPTION OF INNOVATIVE MEDICAL DEVICES WITHIN FRENCH HOSPITALS: OPPORTUNITIES AND CHALLENGES FOR INDUSTRY. *Int J Technol Assess Health Care*. 2017;33:297-302. doi: 10.1017/S0266462317000368. PubMed PMID: 28578711.
 26. Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remona J, Soria JC, Lacroix L, Besse B. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. *Lung Cancer* 2017;112:62-68. doi: 10.1016/j.lungcan.2017.08.002.
 27. Foulon S, Maura G, Dalichampt M, Alla F, Debouverie M, Moreau T, Weill A. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a

study based on French health insurance data. *J Neurol*. 2017;264:1185-92. doi: 10.1007/s00415-017-8513-0. PubMed PMID: 28516332.

28. Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G. Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). *Pediatr Blood Cancer*. 2017;64. doi: 10.1002/pbc.26457. PubMed PMID: 28111876.
29. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, Siesling S, van der Zwan JM, Van Eycken L, Visser O, Žakelj MP, Anderson LA, Bella F, Kaire I, Otter R, Stiller CA, Trama A. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. *Lancet Oncol*. 2017;18:1022-39. doi: 10.1016/S1470-2045(17)30445-X. PubMed PMID: 28687376.
30. Gatta G, Trama A, Capocaccia R. Epidemiology of rare cancers and inequalities in oncologic outcomes. *Eur J Surg Oncol*. 2017. doi: 10.1016/j.ejso.2017.08.018. PubMed PMID: 29032924.
31. Gault N, Castañeda-Sanabria J, De Rycke Y, Guillo S, Foulon S, Tubach F. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review. *BMC Med Res Methodol*. 2017;17:25. doi: 10.1186/s12874-016-0278-0. PubMed PMID: 28178924.
32. Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K. Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [*Eur J Cancer* 69 (2016) 151-157]. *Eur J Cancer*. 2017;75:333. doi: 10.1016/j.ejca.2017.02.014. PubMed PMID: 28283351.
33. Gorphe P, Von Tan J, El Bedoui S, Hartl DM, Auperin A, Qassemyar Q, Moya-Plana A, Janot F, Julieron M, Temam S. Early assessment of feasibility and technical specificities of transoral robotic surgery using the da Vinci Xi. *J Robot Surg*. 2017;11:455-61. doi: 10.1007/s11701-017-0679-z. PubMed PMID: 28064382.
34. Guerrini-Rousseau L, Dufour C, Varlet P, Masliah-Planchon J, Bourdeaut F, Guillaud-Bataille M, Abbas R, Bertozzi AI, Fouyssac F, Huybrechts S, Puget S, Bressac-De Paillerets B, Caron O, Sevenet N, Dimaria M, Villebasse S, Delattre O, Valteau-Couanet D, Grill J, Brugieres L. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis. *Neuro-oncology*. 2017. Epub 2017/12/01. doi: 10.1093/neuonc/nox228. PubMed PMID: 29186568.
35. Guigay J, Mertens C, Le Caer H, Michel C, Ortholan C, Aupérin A. [A French multicenter research program for a personalized treatment of elderly head and neck cancer patient]. *Bull Cancer*. 2017;104:816-9. doi: 10.1016/j.bulcan.2017.06.013. PubMed PMID: 28797481.
36. Guyot P, Ades AE, Beasley M, Lueza B, Pignon JP, Welton NJ. Extrapolation of Survival Curves from Cancer Trials Using External Information. *Med Decis Making*. 2017;37(4):353-66. Epub 2016/09/30. doi: 10.1177/0272989X16670604. PubMed PMID: 27681990.

37. Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C, Déandréis D, Goere D, De Baere T, Schlumberger M, Baudin E. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. *Horm Cancer*. 2017;8:330-7. doi: 10.1007/s12672-017-0303-8. PubMed PMID: 28748315.
38. Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Gamiche-Rolland L, Meurice G, Minard-Colin V, Grill J, Brugieres L, Dufour C, Gaspar N, Michiels S, Vassal G, Soria JC, Georger B. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. *Clin Cancer Res*. 2017;23:6101-12. doi: 10.1158/1078-0432.CCR-17-0381. PubMed PMID: 28733441.
39. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden G, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol*. 2017;24:311-35. doi: 10.1097/PAP.000000000000161. PubMed PMID: 28777143.
40. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden G, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C,

Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol.* 2017;24:235-51. doi: 10.1097/PAP.000000000000162. PubMed PMID: 28777142.

41. Henon C, Lissa D, Occean BV, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S. Patient-reported tolerability of adverse events in phase 1 trials. *ESMO Open.* 2017;2:e000148. doi: 10.1136/esmooopen-2016-000148. PubMed PMID: 28761740.
42. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodr e AL, Hansen M, Meirou Y, Sade-Feldman M, Burra A, Kwak SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dr no B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. *Nat Commun.* 2017;8:592. doi: 10.1038/s41467-017-00608-2. PubMed PMID: 28928380.
43. Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardi re A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. *J Med Genet.* 2017;54:607-12. doi: 10.1136/jmedgenet-2016-104402. PubMed PMID: 28592523.
44. Lacas B, Bourhis J, Overgaard J, Zhang Q, Gr goire V, Nankivell M, Zackrisson B, Sztukowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corv  R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Garden AS, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aup rin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol.* 2017;18:1221-37. doi: 10.1016/S1470-2045(17)30458-8. PubMed PMID: 28757375.
45. Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. *J Clin Endocrinol Metab.* 2017;102:1020-31. doi: 10.1210/jc.2016-3284. PubMed PMID: 28359102.
46. Lassau N, Coiffier B, Faivre L, Benatsou B, Bidault S, Girard E, Asselain B, Pitre-Champagnat S, Koscielny S. Study of Inpatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. *Invest Radiol.* 2017;52:148-54. doi: 10.1097/RLI.0000000000000324. PubMed PMID: 28106614.

47. Lassen P, Lacas B, Pignon JP, Trotti A, Zackrisson B, Zhang Q, Overgaard J, Blanchard P. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. *Radiother Oncol*. 2017. doi: 10.1016/j.radonc.2017.10.018. PubMed PMID: 29100700.
48. Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. *Eur Urol*. 2017. doi: 10.1016/j.eururo.2017.09.022. PubMed PMID: 29074061.
49. Lefeuvre D, Rudant J, Foulon S, Alla F, Weill A. Healthcare expenditure of multiple sclerosis patients in 2013: A nationwide study based on French health administrative databases. *Mult Scler J Exp Transl Clin*. 2017;3:2055217317730421. doi: 10.1177/2055217317730421. PubMed PMID: 28932411.
50. Legoupil C, Peltier A, Henry Kagan V, Segouin C, Alberti C, de Massé L, Shelly M, Krastinova E. Out-of-Hospital screening for HIV, HBV, HCV and Syphilis in a vulnerable population, a public health challenge. *AIDS Care*. 2017;29:686-8. doi: 10.1080/09540121.2016.1231886. PubMed PMID: 27626811.
51. Levy A, Bardet E, Lacas B, Pignon JP, Adam J, Lacroix L, Artignan X, Verrelle P, Le Pechoux C. A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. *Oncotarget*. 2017;8(9):15924-33. Epub 2016/10/21. doi: 10.18632/oncotarget.12741. PubMed PMID: 27764781; PMCID: 5362534.
52. Lindsay CR, Faugeron V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. *Ann Oncol*. 2017;28:1523-31. doi: 10.1093/annonc/mdx156. PubMed PMID: 28633480.
53. Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). *Eur J Cancer*. 2017;85:133-45. doi: 10.1016/j.ejca.2017.08.020. PubMed PMID: 28923573.
54. Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. *Lancet Oncol*. 2017;18:52-62. doi: 10.1016/S1470-2045(16)30631-3. PubMed PMID: 27964843.

55. Lueza B, Lacas B, Pignon JP, Occean BV. [New applications for individual participant data meta-analyses of randomized trials]. *Bull Cancer*. 2017;104(2):139-46. Epub 2016/12/03. doi: 10.1016/j.bulcan.2016.10.024. PubMed PMID: 27908441.
56. Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. *Eur J Surg Oncol*. 2017. doi: 10.1016/j.ejso.2017.08.019. PubMed PMID: 29126671.
57. Malka D, Rotolo F, Boige V. First-line treatment in metastatic colorectal cancer: Important or crucial? *Eur J Cancer*. 2017;84:363-6. doi: 10.1016/j.ejca.2017.09.001. PubMed PMID: 28942867.
58. Martelli N, Devaux C, van den Brink H, Billaux M, Pineau J, Prognon P, Borget I. HARMONIZING HEALTH TECHNOLOGY ASSESSMENT PRACTICES IN UNIVERSITY HOSPITALS: TO WHAT EXTENT IS THE MINI-HTA MODEL SUITABLE IN THE FRENCH CONTEXT? *Int J Technol Assess Health Care*. 2017;33:307-14. doi: 10.1017/S0266462317000393. PubMed PMID: 28580892.
59. Martínez-Mesa J, Werutsky G, Michiels S, Pereira Filho CAS, Dueñas-González A, Zarba JJ, Mano M, Villarreal-Garza C, Gómez H, Barrios CH. Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. *Public Health*. 2017;149:81-8. doi: 10.1016/j.puhe.2017.04.017. PubMed PMID: 28577441.
60. Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. *Eur J Cancer*. 2017;83:185-93. doi: 10.1016/j.ejca.2017.05.016. PubMed PMID: 28743036.
61. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. *Cancer Discov*. 2017;7:586-95. doi: 10.1158/2159-8290.CD-16-1396. PubMed PMID: 28365644.
62. Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. *Eur J Cancer*. 2017;79:185-92. doi: 10.1016/j.ejca.2017.04.015. PubMed PMID: 28511146.
63. Mauguen A, Michiels S, Rondeau V. Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events. *J Biopharm Stat*. 2017:1-11. doi: 10.1080/10543406.2017.1295249. PubMed PMID: 28319455.
64. Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer. *Lung Cancer* 2017;112:10-15. doi: 10.1016/j.lungcan.2017.07.004.

65. Michiels S, Saad ED, Buyse M. Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors". *Drugs*. 2017;77:1139-40. doi: 10.1007/s40265-017-0761-x. PubMed PMID: 28573433.
66. Michiels S, Saad ED, Buyse M. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. *Drugs*. 2017;77:713-9. doi: 10.1007/s40265-017-0728-y. PubMed PMID: 28337673.
67. Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Occean BV, Ribrag V. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. *Invest New Drugs*. 2017. doi: 10.1007/s10637-017-0480-x. PubMed PMID: 28597151.
68. Mirghani H, Sturgis EM, Auperin A, Monsonego J, Blanchard P. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. *Oral oncology*. 2017;67:138-45. Epub 2017/03/30. doi: 10.1016/j.oraloncology.2017.02.024. PubMed PMID: 28351568.
69. Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E. Are we reproducible in measurement of NET liver metastasis? *Dig Liver Dis*. 2017;49:1121-7. doi: 10.1016/j.dld.2017.05.015. PubMed PMID: 28844707.
70. Moreno L, Pearson ADJ, Occean BV, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. *Nat Rev Clin Oncol*. 2017;14:497-507. doi: 10.1038/nrclinonc.2017.59. PubMed PMID: 28508875.
71. Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Occean BV, Pearson AD. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. *Pediatr Blood Cancer*. 2017;64(1):25-31. Epub 2016/08/25. doi: 10.1002/pbc.26192. PubMed PMID: 27555472.
72. Motte AF, Diallo S, van den Brink H, Châteauvieux C, Serrano C, Naud C, Steelandt J, Alsac JM, Aubry P, Cour F, Pellerin O, Pineau J, Prognon P, Borget I, Bonan B, Martelli N. Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic review. *J Clin Epidemiol*. 2017. doi: 10.1016/j.jclinepi.2017.07.005. PubMed PMID: 28728922.
73. Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. *Clin Genet*. 2017;92:606-15. doi: 10.1111/cge.13014. PubMed PMID: 28300276.
74. Pages A, Foulon S, Zou Z, Lacroix L, Lemare F, de Baere T, Massard C, Soria JC, Bonastre J. The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. *Genetics in medicine : official journal of the*

American College of Medical Genetics. 2017;19(6):683-90. Epub 2016/12/03. doi: 10.1038/gim.2016.174. PubMed PMID: 27906201.

75. Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. *Cancer Res.* 2017;77:2222-30. doi: 10.1158/0008-5472.CAN-16-3072. PubMed PMID: 28461563.
76. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *N Engl J Med.* 2017;377:1836-46. doi: 10.1056/NEJMoa1701830. PubMed PMID: 29117498.
77. Occean BV, Drubay D, Collette L. Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes. *Clin Cancer Res.* 2017;23:3977-9. doi: 10.1158/1078-0432.CCR-17-1306. PubMed PMID: 28630213.
78. Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, Gronchi A. Treatment challenges in and outside a network setting: Soft tissue sarcomas. *Eur J Surg Oncol.* 2017. doi: 10.1016/j.ejso.2017.09.015. PubMed PMID: 28985973.
79. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol.* 2017. doi: 10.1016/j.ejso.2017.09.025. PubMed PMID: 29108961.
80. Ribassin-Majed L, Le Teuff G, Hil C. [Erratum to: "The frequency of cancer in France: Most recent data and trends" [*Bull. Cancer* 104 (2017) 20-29]]. *Bull Cancer.* 2017;104:388. doi: 10.1016/j.bulcan.2017.02.001. PubMed PMID: 28302268.
81. Ribassin-Majed L, Le-Teuff G, Hil C. [The frequency of cancer in France: Most recent data and trends]. *Bull Cancer.* 2017;104:20-9. doi: 10.1016/j.bulcan.2016.11.003. PubMed PMID: 28007294.
82. Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y, Mai HQ, Kwong DLW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2017;35(5):498-505. Epub 2016/12/06. doi: 10.1200/JCO.2016.67.4119. PubMed PMID: 27918720.
83. Riet FG, Fayard F, Arriagada R, Santos MA, Bourgier C, Ferchiou M, Heymann S, Delalogue S, Mazouni C, Dunant A, Rivera S. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. *Eur J Cancer.* 2017;76:45-51. doi: 10.1016/j.ejca.2017.01.022. PubMed PMID: 28267657.
84. Rivin Del Campo E, Rivera S, Martínez-Paredes M, Hupé P, Slocker Escarpa A, Borget I, Mazon R, Scholl S, Palacios Eito A, Haie-Meder C, Chargari C, Deutsch E. Assessment of the novel online delineation workshop dummy run approach using FALCON within a European multicentre trial in cervical cancer (RAIDs). *Radiother Oncol.* 2017;124:130-8. doi: 10.1016/j.radonc.2017.05.008. PubMed PMID: 28532608.

85. Rotolo F, Occean BV, Burzykowski T, Buyse M, Michiels S. A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. *Stat Methods Med Res.* 2017;962280217718582. doi: 10.1177/0962280217718582. PubMed PMID: 28681681.
86. Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. *J Natl Cancer Inst.* 2017;109. doi: 10.1093/jnci/djw239. PubMed PMID: 27927756.
87. Saad ED, Occean BV, Burzykowski T, Buyse M. Precision medicine needs randomized clinical trials. *Nat Rev Clin Oncol.* 2017;14:317-23. doi: 10.1038/nrclinonc.2017.8. PubMed PMID: 28169302.
88. Saâda-Bouزيد E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Occean BV, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol.* 2017;28:1605-11. doi: 10.1093/annonc/mdx178. PubMed PMID: 28419181.
89. Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, Ghez D, Lazarovici J, Michot JM, Khalife-Saleh N, Lapierre V, Alenxandrova K, Arfi-Rouche J, Bourhis JH, Ribrag V. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. *Leuk Lymphoma.* 2017;1-8. doi: 10.1080/10428194.2017.1403019. PubMed PMID: 29164977.
90. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D. Societal challenges of precision medicine: Bringing order to chaos. *Eur J Cancer.* 2017;84:325-34. doi: 10.1016/j.ejca.2017.07.028. PubMed PMID: 28865260.
91. Shepherd FA, Lacas B, Le Teuff G, Hainaut P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY, Graziano S, Brambilla E, Pirker R, Filipits M, Kratzke R, Soria JC, Tsao MS. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. *J Clin Oncol.* 2017;35:2018-27. doi: 10.1200/JCO.2016.71.2893. PubMed PMID: 28453411.
92. Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. *Eur J Cancer.* 2017;75:259-67. doi: 10.1016/j.ejca.2016.11.034. PubMed PMID: 28242503.
93. Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. *Oral Oncol.* 2017;71:61-6. doi: 10.1016/j.oraloncology.2017.06.002. PubMed PMID: 28688693.

94. Ternes N, Rotolo F, Heinze G, Michiels S. Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. *Biometrical journal Biometrische Zeitschrift*. 2017;59(4):685-701. Epub 2016/11/20. doi: 10.1002/bimj.201500234. PubMed PMID: 27862181.
95. Ternès N, Rotolo F, Michiels S. biospear: an R package for biomarker selection in penalized Cox regression. *Bioinformatics*. 2017. doi: 10.1093/bioinformatics/btx560. PubMed PMID: 28927242.
96. Ternès N, Rotolo F, Michiels S. Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. *BMC Med Res Methodol*. 2017;17:83. doi: 10.1186/s12874-017-0354-0. PubMed PMID: 28532387.
97. Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2017;44(4):638-46. Epub 2016/11/01. doi: 10.1007/s00259-016-3551-x. PubMed PMID: 27796544.
98. Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. *Ann Oncol*. 2017;28:882-9. doi: 10.1093/annonc/mdx003. PubMed PMID: 28137741.
99. Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. *Eur J Cancer*. 2017;87:122-30. doi: 10.1016/j.ejca.2017.10.013. PubMed PMID: 29145038.
100. Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. *Ann Oncol*. 2017. doi: 10.1093/annonc/mdx707. PubMed PMID: 29140430.
101. Yin J, O'cean BV, Sargent DJ, Mandrekar SJ. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. *Clinical trials*. 2017;1740774517723829. doi: 10.1177/1740774517723829. PubMed PMID: 28764555.
102. Król A, Mauguen A, Mazroui Y, Laurent A, Michiels S, Rondeau V. Tutorial in Joint Modeling and Prediction: A Statistical Software for Correlated Longitudinal Outcomes, Recurrent Events and a Terminal Event *Journal of Statistical Software* 2017; 81:3;1-52.
103. Assayag M, Abbas R, Chanson N, Perozziello A, Ducrocq G, Alexandra JF, Dossier A, Papo T, Sacre K. Diagnosis of systemic inflammatory diseases among patients admitted for acute pericarditis with pericardial effusion. *J Cardiovasc Med (Hagerstown)*. 2017 Nov;18(11):875-880. doi: 10.2459/JCM.0000000000000576. PubMed PMID: 28937580.

104. Divard G, Abbas R, Chenevier-Gobeaux C, Chanson N, Escoubet B, Chauveheid MP, Dossier A, Papo T, Dehoux M, Sacre K. High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematosus patients: a cross-sectional controlled study. *Arthritis Res Ther*. 2017 Jun 13;19(1):132. doi:10.1186/s13075-017-1352-7. PubMed PMID: 28610589; PubMed Central PMCID:PMC5470230.
105. Asselain B, Océan BV. Enjeux méthodologiques de la médecine de précision en oncologie. *Innovations & Thérapeutiques en Oncologie*, 2017;3(1):33-38.
106. Tabone MD, Brugières L, Piperno-Neumann S, Selva MA, Marec-Bérard P, Pacquement H, Lervat C, Corradini N, Gentet JC, Couderc R, Chevance A, Mahier-Ait Oukhatar C, Entz-Werle N, Blay JY, Le Deley MC. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. *BMC Cancer*. 2017 Jun 15;17(1):419. doi:10.1186/s12885-017-3409-z. PubMed PMID: 28619014; PubMed Central PMCID: PMC5473001.
107. Hollebecque A, Bahleda R, Faivre L, Adam J, Poinignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. *Eur J Cancer*. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12. PubMed PMID: 28618305.
108. Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. *Invest New Drugs*. 2017 Nov 2. doi: 10.1007/s10637-017-0531-3. [Epub ahead of print] PubMed PMID: 29094232.
109. Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. *J Invest Dermatol*. 2017 May;137(5):1065-1073. doi: 10.1016/j.jid.2016.11.034. Epub 2016 Dec 21.
110. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, Leary AF. *Ann Oncol*. 2017 Mar 1;28(3):651-657. doi: 10.1093/annonc/mdw625.
111. Gaspar N, Océan BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugières L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. *Eur J Cancer*. 2017 Nov 27;88:57-66.

